Sleep Disorders

Article

A Narcolepsy Primer, With a Focus on Xyrem

Narcolepsy affects about 1 out of 2000 people, for a prevalence rate of 0.05%. This puts it officially in the category of rare diseases. So why are we asking you to read about such a rare disorder? Partly because there’s a lot of comorbidity between narcolepsy and most psychiatric disorders. And partly because Jazz Pharmaceuticals is placing lots of ads in psychiatric journals urging us to diagnose more narcolepsy so that we’ll use their new drug Xyrem.

Belsomra: A New Hypnotic? Don’t Get Too Excited

In the wake (pun intended) of last year’s FDA warnings of next-morning impairment and the lower dosing recommendations for “Z drugs,” wouldn’t now be the perfect time for a new hypnotic to enter the marketplace?

Seven Clinical Pearls for Suicide Risk Assessment

Risk Management - The Carlat Psychiatry Report - June 2012

Assessing a patient’s risk of suicide is one of the most common, yet challenging, exercises for the psychiatrist.

Free Article

Belsomra: A New Hypnotic? Don’t Get Too Excited [Free Article]

Source: 
Pharmacogenetics
Pharmacogenetics - The Carlat Psychiatry Report (TCPR)

In the wake (pun intended) of last year’s FDA warnings of next-morning impairment and the lower dosing recommendations for “Z drugs,” wouldn’t now be the perfect time for a new hypnotic to enter the marketplace?

Seven Clinical Pearls for Suicide Risk Assessment [Free Article]

Source: 
Risk Management
Risk Management - The Carlat Psychiatry Report - June 2012

Assessing a patient’s risk of suicide is one of the most common, yet challenging, exercises for the psychiatrist.